CRSTI
7777 Forest Lane
Suite C-742
Dallas, TX 75230
972-566-6820
fax: 972-566-8524
info@crsti.org
Open TrialsMAGRIT Trial: Double-blind, Randomized, Placebo-controlled
Phase III Study to Assess Efficacy of recMAGE-A3 + AS15 as Adjuvant
Therapy in patients with resectable MAGE-A3-positive Non-Small Cell
Lung Cancer
Sponsor: GlaxoSmithKline Biological (GSK)
Investigator: Mitchell Magee, MD
Research Coordinator: Kimberly Ewing
Designated Site: CSANT; Medical City Dallas Hospital
Cardiopulmonary Research Science and Technology Institute (CRSTI)
The purpose of study is to measure how well the MAGE-A3 works in preventing NSCLC from recurring after the removal of tumor by surgery. A total of 13 injections will be made in the muscle of upper arm; the first 5 injections will be given every 3 weeks and the next 8 every 3 months. Outcome will be measured X-rays or CT scans, blood tests and physical examinations. The study will take place over a period of 30 months.